Charles Homcy

Fondateur chez BRIDGEBIO PHARMA, INC. Fortune : 62 M $ au 31/05/2026

Profil

Charles J.
Homcy founded Portola Pharmaceuticals LLC in 2003, where he worked as Co-Chairman, President & Chief Executive Officer, Global Blood Therapeutics, Inc. in 2011, where he worked as Independent Director from 2012 to 2019, BridgeBio Pharma, Inc. in 2015, where he is working as Lead Director & Chairman-Pharmaceuticals from 2020, and BridgeBio Pharma LLC in 2018, where he worked as Director & Chairman-Pharmaceuticals from 2019 to 2020.
Dr. Homcy also founded Relay Therapeutics, Inc. and Marea Therapeutics, Inc. Dr. Homcy also currently works at CytomX Therapeutics Holdings LLC, as Director from 2012, Ambys Medicines, Inc., as Director, Maze Therapeutics, Inc., as Director from 2025, Population Health Investment Co., Inc., as Independent Director, The Johns Hopkins University, as Trustee, and Third Rock Ventures LLC, as Partner from 2010 to 2022.
Dr. Homcy also formerly worked at Cephalon LLC, as Director in 2011, COR Therapeutics, Inc., as Director, Executive VP-Research & Development from 1998 to 2002, Millennium Pharmaceuticals, Inc., as Director from 2002 to 2008, Geron Corp., as Director, Kosan Biosciences, Inc., as Director from 2003 to 2008, Cytokinetics, Inc., as Director in 2008, MyoKardia, Inc., as Non-Employee Class II Director from 2013 to 2017, Topica Pharmaceuticals, Inc., as Director, Pliant Therapeutics, Inc., as Independent Director from 2015 to 2022, Wyeth Holdings LLC, as President-Medical Research, The Trustees of Columbia University in The City of New York, as Professor in 1995, The General Hospital Corp., as Principal in 1990, The University of California, San Francisco, as Professor, Lederle Laboratories, as President-Medical Research Division from 1990 to 1994, Harvard Medical School, as Associate Professor in 1990, Presbyterian Hospital, Inc., as Clinical Professor in 1995, and UCSF School of Medicine, as Clinical Professor.
Dr. Homcy received his undergraduate degree and doctorate degree from The Johns Hopkins University.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
BRIDGEBIO PHARMA, INC. 0,47%	22/06/2026	919 876 ( 0,47% )	61 M $	31/05/2026
Maze Therapeutics, Inc. 0,06%	08/06/2026	31 113 ( 0,06% )	823 250 $	31/05/2026

Postes actifs de Charles Homcy

Sociétés	Poste	Début
BRIDGEBIO PHARMA, INC.	Fondateur	01/01/2015
POPULATION HEALTH INVESTMENT CO., INC.	Directeur/Membre du Conseil	-
Maze Therapeutics, Inc.	Directeur/Membre du Conseil	06/10/2025
Ambys Medicines, Inc.	Directeur/Membre du Conseil	-
The Johns Hopkins University	Directeur/Membre du Conseil	-
Third Rock Ventures LLC	Consultant / Advisor	01/01/2010
CytomX Therapeutics Holdings LLC	Directeur/Membre du Conseil	06/10/2010

Anciens postes connus de Charles Homcy

Sociétés	Poste	Fin
PLIANT THERAPEUTICS, INC.	Directeur/Membre du Conseil	16/06/2022
GLOBAL BLOOD THERAPEUTICS, INC.	Fondateur	18/06/2019
░░░░░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░	░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░
░░░░░░░░░░░░░ ░░░░░░░░░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	░░░░░░░░░░